Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes.

Denlinger-Apte RL, Tidey JW, Koopmeiners JS, Hatsukami DK, Smith TT, Pacek LR, McClernon FJ, Donny EC.

Tob Control. 2018 Nov 1. pii: tobaccocontrol-2018-054622. doi: 10.1136/tobaccocontrol-2018-054622. [Epub ahead of print]

PMID:
30385649
2.

Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users.

Benowitz NL, Flanagan CA, Thomas TK, Koller KR, Wolfe AW, Renner CC, Hughes C, Decker PA, Hatsukami DK, Murphy NJ, Patten C.

Int J Circumpolar Health. 2018 Dec;77(1):1528125. doi: 10.1080/22423982.2018.1528125.

3.

The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller.

Hatsukami DK, Donny EC.

Nicotine Tob Res. 2018 Oct 12. doi: 10.1093/ntr/nty195. [Epub ahead of print] No abstract available.

PMID:
30312443
4.

Reducing Nicotine in Cigarettes to Minimally Addictive Levels: A New Frontier for Tobacco Control.

Hatsukami DK.

JAMA Psychiatry. 2018 Oct 1;75(10):987-988. doi: 10.1001/jamapsychiatry.2018.1829. No abstract available.

PMID:
30285225
5.

Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.

Hatsukami DK, Luo X, Jensen JA, al'Absi M, Allen SS, Carmella SG, Chen M, Cinciripini PM, Denlinger-Apte R, Drobes DJ, Koopmeiners JS, Lane T, Le CT, Leischow S, Luo K, McClernon FJ, Murphy SE, Paiano V, Robinson JD, Severson H, Sipe C, Strasser AA, Strayer LG, Tang MK, Vandrey R, Hecht SS, Benowitz NL, Donny EC.

JAMA. 2018 Sep 4;320(9):880-891. doi: 10.1001/jama.2018.11473.

PMID:
30193275
6.

Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers.

Murphy SE, Park SL, Balbo S, Haiman CA, Hatsukami DK, Patel Y, Peterson LA, Stepanov I, Stram DO, Tretyakova N, Hecht SS, Le Marchand L.

NPJ Precis Oncol. 2018 Aug 22;2:17. doi: 10.1038/s41698-018-0057-y. eCollection 2018. Review.

7.

Presence of the Carcinogen N'-Nitrosonornicotine in Saliva of E-cigarette Users.

Bustamante G, Ma B, Yakovlev G, Yershova K, Le C, Jensen J, Hatsukami DK, Stepanov I.

Chem Res Toxicol. 2018 Aug 20;31(8):731-738. doi: 10.1021/acs.chemrestox.8b00089. Epub 2018 Jul 30.

PMID:
30019582
8.

Cigarette and e-liquid demand and substitution in e-cigarette-naïve smokers.

Stein JS, Koffarnus MN, Stepanov I, Hatsukami DK, Bickel WK.

Exp Clin Psychopharmacol. 2018 Jun;26(3):233-243. doi: 10.1037/pha0000192.

PMID:
29863381
9.

Patterns of Tobacco Cessation Attempts and Symptoms Experienced Among Smokers With Head and Neck Squamous Cell Carcinoma.

Khariwala SS, Hatsukami DK, Stepanov I, Rubin N, Nelson HH.

JAMA Otolaryngol Head Neck Surg. 2018 Jun 1;144(6):477-482. doi: 10.1001/jamaoto.2018.0249.

PMID:
29800964
10.

Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health.

Smith TT, Hatsukami DK, Benowitz NL, Colby SM, McClernon FJ, Strasser AA, Tidey JW, White CM, Donny EC.

Prev Med. 2018 Dec;117:8-14. doi: 10.1016/j.ypmed.2018.03.021. Epub 2018 Mar 29.

PMID:
29604326
11.

Strong preference for mint snus flavor among research participants.

Schneller LM, Lindgren BR, Shields PG, Hatsukami DK, O'Connor RJ.

Addict Behav Rep. 2017 Jul 31;6:51-55. doi: 10.1016/j.abrep.2017.07.004. eCollection 2017 Dec.

12.

Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop.

Chang CM, Cheng YC, Cho TM, Mishina EV, Del Valle-Pinero AY, van Bemmel DM, Hatsukami DK.

Nicotine Tob Res. 2019 Jan 1;21(1):3-13. doi: 10.1093/ntr/ntx273.

PMID:
29253243
13.

Effects of Filter Ventilation on Behavioral Economic Demand for Cigarettes: A Preliminary Investigation.

Stein JS, Koffarnus MN, O'Connor RJ, Hatsukami DK, Bickel WK.

Nicotine Tob Res. 2018 Sep 4;20(10):1278-1282. doi: 10.1093/ntr/ntx164.

PMID:
29065197
14.

Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus.

Berman ML, Bickel WK, Harris AC, LeSage MG, O'Connor RJ, Stepanov I, Shields PG, Hatsukami DK.

Nicotine Tob Res. 2018 Sep 25;20(11):1292-1300. doi: 10.1093/ntr/ntx228.

PMID:
29059363
15.

Evaluating the utility of subjective effects measures for predicting product sampling, enrollment, and retention in a clinical trial of a smokeless tobacco product.

O'Connor RJ, Lindgren BR, Schneller LM, Shields PG, Hatsukami DK.

Addict Behav. 2018 Jan;76:95-99. doi: 10.1016/j.addbeh.2017.07.025. Epub 2017 Jul 14.

PMID:
28772248
16.

Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks.

Pacek LR, Joseph McClernon F, Denlinger-Apte RL, Mercincavage M, Strasser AA, Dermody SS, Vandrey R, Smith TT, Nardone N, Hatsukami DK, Koopmeiners JS, Kozink RV, Donny EC.

Tob Control. 2018 Jul;27(4):420-426. doi: 10.1136/tobaccocontrol-2017-053689. Epub 2017 Jul 22.

PMID:
28735272
17.

High Level of Tobacco Carcinogen-Derived DNA Damage in Oral Cells Is an Independent Predictor of Oral/Head and Neck Cancer Risk in Smokers.

Khariwala SS, Ma B, Ruszczak C, Carmella SG, Lindgren B, Hatsukami DK, Hecht SS, Stepanov I.

Cancer Prev Res (Phila). 2017 Sep;10(9):507-513. doi: 10.1158/1940-6207.CAPR-17-0140. Epub 2017 Jul 5.

18.

Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco.

Berman ML, Hatsukami DK.

Tob Control. 2018 May;27(3):352-354. doi: 10.1136/tobaccocontrol-2016-053612. Epub 2017 Jun 20.

19.

Sex differences in physiological response to the combination of stress and smoking.

Kotlyar M, Thuras P, Hatsukami DK, al'Absi M.

Int J Psychophysiol. 2017 Aug;118:27-31. doi: 10.1016/j.ijpsycho.2017.05.008. Epub 2017 May 23.

20.

Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.

Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, Marian C, O'Connor R, Rees VW, Woroszylo C, Shields PG.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx075. Review.

21.

Internalized smoking stigma in relation to quit intentions, quit attempts, and current e-cigarette use.

O'Connor RJ, Rees VW, Rivard C, Hatsukami DK, Cummings KM.

Subst Abus. 2017 Jul-Sep;38(3):330-336. doi: 10.1080/08897077.2017.1326999. Epub 2017 May 8.

22.

Cigarette Nicotine Content as a Moderator of the Relationship Between Negative Affect and Smoking.

Robinson JD, Kypriotakis G, Karam-Hage M, Green CE, Hatsukami DK, Cinciripini PM, Donny EC.

Nicotine Tob Res. 2017 Sep 1;19(9):1080-1086. doi: 10.1093/ntr/ntx068.

23.

Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Murphy SE, Sipe CJ, Choi K, Raddatz LM, Koopmeiners JS, Donny EC, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1093-1099. doi: 10.1158/1055-9965.EPI-16-0920. Epub 2017 Mar 6.

24.

Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms.

Kotlyar M, Lindgren BR, Vuchetich JP, Le C, Mills AM, Amiot E, Hatsukami DK.

Addict Behav. 2017 Aug;71:18-24. doi: 10.1016/j.addbeh.2017.02.018. Epub 2017 Feb 10.

25.

Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop.

Chang CM, Edwards SH, Arab A, Del Valle-Pinero AY, Yang L, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302. doi: 10.1158/1055-9965.EPI-16-0675. Epub 2016 Nov 9.

26.

Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial.

Hatsukami DK, Luo X, Dick L, Kangkum M, Allen SS, Murphy SE, Hecht SS, Shields PG, al'Absi M.

Addiction. 2017 Jan;112(1):156-167. doi: 10.1111/add.13603. Epub 2016 Nov 2.

27.

Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial.

Smith TT, Cassidy RN, Tidey JW, Luo X, Le CT, Hatsukami DK, Donny EC.

Addiction. 2017 Feb;112(2):349-359. doi: 10.1111/add.13636. Epub 2016 Nov 28.

28.

Optimized Liquid Chromatography Nanoelectrospray-High-Resolution Tandem Mass Spectrometry Method for the Analysis of 4-Hydroxy-1-(3-pyridyl)-1-butanone-Releasing DNA Adducts in Human Oral Cells.

Ma B, Ruszczak C, Jain V, Khariwala SS, Lindgren B, Hatsukami DK, Stepanov I.

Chem Res Toxicol. 2016 Nov 21;29(11):1849-1856. Epub 2016 Oct 12.

29.

Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms.

Tidey JW, Pacek LR, Koopmeiners JS, Vandrey R, Nardone N, Drobes DJ, Benowitz NL, Dermody SS, Lemieux A, Denlinger RL, Cassidy R, al'Absi M, Hatsukami DK, Donny EC.

Nicotine Tob Res. 2017 Jan;19(1):59-67. Epub 2016 Aug 3.

30.

Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use.

Pacek LR, Vandrey R, Dermody SS, Denlinger-Apte RL, Lemieux A, Tidey JW, McClernon FJ, Bangdiwala AS, Drobes DJ, al'Absi M, Strasser AA, Koopmeiners JS, Hatsukami DK, Donny EC.

Drug Alcohol Depend. 2016 Oct 1;167:228-32. doi: 10.1016/j.drugalcdep.2016.08.620. Epub 2016 Aug 28.

31.

Application of the Smokeless Tobacco Expectancies Questionnaire to Snus.

Adkison SE, Bansal-Travers M, Rees VW, Hatsukami DK, Cummings KM, O'Connor RJ.

Am J Health Behav. 2016 Sep;40(5):652-8. doi: 10.5993/AJHB.40.5.12.

32.

Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game.

Benowitz NL, Donny EC, Hatsukami DK.

Addiction. 2017 Jan;112(1):6-7. doi: 10.1111/add.13534. Epub 2016 Aug 23. No abstract available.

33.

Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis.

Chen LS, Baker T, Hung RJ, Horton A, Culverhouse R, Hartz S, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, Horsman J, Kim C, Rosenberger A, Aben KK, Andrew AS, Chang SC, Saum KU, Dienemann H, Hatsukami DK, Johnson EO, Pande M, Wrensch MR, McLaughlin J, Skaug V, van der Heijden EH, Wampfler J, Wenzlaff A, Woll P, Zienolddiny S, Bickeböller H, Brenner H, Duell EJ, Haugen A, Brüske I, Kiemeney LA, Lazarus P, Le Marchand L, Liu G, Mayordomo J, Risch A, Schwartz AG, Teare MD, Wu X, Wiencke JK, Yang P, Zhang ZF, Spitz MR, Amos CI, Bierut LJ.

EBioMedicine. 2016 Sep;11:219-226. doi: 10.1016/j.ebiom.2016.08.012. Epub 2016 Aug 10.

34.

Harnessing the Power of Cruciferous Vegetables: Developing a Biomarker for Brassica Vegetable Consumption Using Urinary 3,3'-Diindolylmethane.

Fujioka N, Ransom BW, Carmella SG, Upadhyaya P, Lindgren BR, Roper-Batker A, Hatsukami DK, Fritz VA, Rohwer C, Hecht SS.

Cancer Prev Res (Phila). 2016 Oct;9(10):788-793. Epub 2016 Aug 18.

35.

A review of the additive health risk of cannabis and tobacco co-use.

Meier E, Hatsukami DK.

Drug Alcohol Depend. 2016 Sep 1;166:6-12. doi: 10.1016/j.drugalcdep.2016.07.013. Epub 2016 Jul 25. Review.

PMID:
27476751
36.

Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes.

Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, Murphy SE, Strasser AA, Tidey JW, Vandrey R, Benowitz NL.

Addiction. 2016 Dec;111(12):2208-2216. doi: 10.1111/add.13519. Epub 2016 Aug 1.

37.

The case for the WHO Advisory Note, Global Nicotine Reduction Strategy.

Hatsukami DK, Zaatari G, Donny E.

Tob Control. 2017 Mar;26(e1):e29-e30. doi: 10.1136/tobaccocontrol-2016-053134. Epub 2016 Jun 29. No abstract available.

38.

Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.

Mooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK.

Clin Pharmacol Ther. 2016 Oct;100(4):344-52. doi: 10.1002/cpt.402. Epub 2016 Jun 20.

39.

Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings.

Flanagan CA, Koller KR, Wolfe AW, Thomas TK, Benowitz NL, Renner CC, Hughes C, Hatsukami DK, Bronars C, Murphy NJ, Day G, Decker PA, Patten CA.

Nicotine Tob Res. 2016 Nov;18(11):2162-2168. Epub 2016 May 17.

40.

Persistence and amplitude of cigarette demand in relation to quit intentions and attempts.

O'Connor RJ, Heckman BW, Adkison SE, Rees VW, Hatsukami DK, Bickel WK, Cummings KM.

Psychopharmacology (Berl). 2016 Jun;233(12):2365-71. doi: 10.1007/s00213-016-4286-x. Epub 2016 Apr 6.

41.

Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes.

Denlinger RL, Smith TT, Murphy SE, Koopmeiners JS, Benowitz NL, Hatsukami DK, Pacek LR, Colino C, Cwalina SN, Donny EC.

Tob Regul Sci. 2016 Apr;2(2):186-203. doi: 10.18001/TRS.2.2.9.

42.

Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research.

Land SR, Warren GW, Crafts JL, Hatsukami DK, Ostroff JS, Willis GB, Chollette VY, Mitchell SA, Folz JN, Gulley JL, Szabo E, Brandon TH, Duffy SA, Toll BA.

Cancer. 2016 Jun 1;122(11):1728-34. doi: 10.1002/cncr.29964. Epub 2016 Mar 28.

43.

The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use.

Dermody SS, Tidey JW, Denlinger RL, Pacek LR, al'Absi M, Drobes DJ, Hatsukami DK, Vandrey R, Donny EC.

Alcohol Clin Exp Res. 2016 Mar;40(3):606-15. doi: 10.1111/acer.12980. Epub 2016 Feb 25.

44.

Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research.

Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW.

Clin Cancer Res. 2016 Apr 15;22(8):1907-13. doi: 10.1158/1078-0432.CCR-16-0104. Epub 2016 Feb 17.

45.

Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass Spectrometry.

von Weymarn LB, Thomson NM, Donny EC, Hatsukami DK, Murphy SE.

Chem Res Toxicol. 2016 Mar 21;29(3):390-7. doi: 10.1021/acs.chemrestox.5b00521. Epub 2016 Feb 12.

46.

Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Donny EC, Hatsukami DK.

N Engl J Med. 2016 Jan 28;374(4):396-7. doi: 10.1056/NEJMc1513886. No abstract available.

PMID:
26816022
47.

Providing a Science Base for the Evaluation of Tobacco Products.

Berman ML, Connolly G, Cummings KM, Djordjevic MV, Hatsukami DK, Henningfield JE, Myers M, O'Connor RJ, Parascandola M, Rees V, Rice JM, Shields PG.

Tob Regul Sci. 2015 Apr;1(1):76-93.

48.

Preference for Flavored Noncombustible Nicotine Products Among Smokers Motivated to Switch From Cigarettes.

Meier E, Isaksson Vogel R, O'Connor RJ, Severson HH, Shields PG, Hatsukami DK.

Nicotine Tob Res. 2016 May;18(5):892-3. doi: 10.1093/ntr/ntv259. Epub 2015 Nov 25. No abstract available.

49.

Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking.

Konorev D, Koopmeiners JS, Tang Y, Franck Thompson EA, Jensen JA, Hatsukami DK, Turesky RJ.

Chem Res Toxicol. 2015 Dec 21;28(12):2390-9. doi: 10.1021/acs.chemrestox.5b00401. Epub 2015 Dec 3.

50.

Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, Benowitz NL, Vandrey RG, al'Absi M, Carmella SG, Cinciripini PM, Dermody SS, Drobes DJ, Hecht SS, Jensen J, Lane T, Le CT, McClernon FJ, Montoya ID, Murphy SE, Robinson JD, Stitzer ML, Strasser AA, Tindle H, Hatsukami DK.

N Engl J Med. 2015 Oct;373(14):1340-9. doi: 10.1056/NEJMsa1502403.

Supplemental Content

Loading ...
Support Center